Skip to main content

Table 4 Incremental ability of various IR surrogates on the prediction of MACCE in the total population

From: Comparison of various insulin resistance surrogates on prognostic prediction and stratification following percutaneous coronary intervention in patients with and without type 2 diabetes mellitus

 

Harrell’s C-index

Continuous NRI

IDI

 

Est. (95% CI)

ΔEst

P-value

Est. (95% CI)

P-value

Est. (95% CI)

P-value

Baseline modela

0.708 (0.672–0.744)

–

–

–

–

–

–

+ TyG index

0.758 (0.726–0.791)

0.050

 < 0.001

0.255 (0.145–0.320)

 < 0.001

0.033 (0.012–0.058)

 < 0.001

+ VAI

0.734 (0.700–0.769)

0.026

0.004

0.149 (0.076–0.244)

 < 0.001

0.025 (0.010–0.046)

 < 0.001

+ CVAI

0.726 (0.692–0.761)

0.018

0.029

0.168 (0.033–0.239)

0.007

0.008 (0.000–0.023)

0.033

+ LAP

0.742 (0.707–0.777)

0.034

 < 0.001

0.155 (0.060–0.233)

 < 0.001

0.026 (0.009–0.053)

 < 0.001

+ TG/HDL-C

0.731 (0.696-.0766)

0.023

 < 0.001

0.134 (0.054–0.227)

 < 0.001

0.020 (0.006–0.041)

 < 0.001

  1. TyG triglyceride-glucose, VAI visceral adiposity index, CVAI Chinese visceral adiposity index, LAP lipid accumulation product, TG/HDL-C triglyceride-to-high density lipoprotein cholesterol ratio, NRI net reclassification improvement, IDI integrated discrimination improvement, CI confidence interval
  2. aThe baseline model incorporates smoking history, hypertension, T2DM, previous MI, previous PCI, previous stroke, TC, eGFR, HbA1c, LVEF, LM disease, three-vessel disease, SYNTAX score, and number of stents